Journal of stomatology, oral and maxillofacial surgery · 2025
VEGF mRNA expression as a powerful independent predictor for recurrence in ameloblastoma: Integrating molecular profiling with surgical outcome analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Yao, Liu Ke, Lu Yifan, Gan Min
Аннотация
OBJECTIVE: To investigate vascular endothelial growth factor (VEGF) mRNA expression as an independent biomarker for predicting recurrence in ameloblastoma (AM), and to evaluate its potential for guiding surgical strategy.
METHODS: A retrospective cohort study was conducted involving 200 patients with primary AM undergoing initial surgery during January 2021-December 2023. Patients were categorized into curettage (n = 77) and extended resection (n = 123) groups. Relative VEGF mRNA expression in the tumor cyst wall was quantified using RT-qPCR. Kaplan-Meier analysis and Cox regression were used to analyze recurrence-free survival (RFS) and risk factors. Perioperative outcomes and complications were compared between groups. Univariate and multivariate analyses were performed using Cox proportional hazards regression models.
RESULTS: VEGF mRNA expression was significantly elevated in the recurrence group (4.66 ± 1.42) versus the non-recurrence group (3.24 ± 2.02, P < 0.001). ROC curve analysis identified an optimal VEGF cutoff value of 4.88 for predicting recurrence (AUC = 0.694). This molecular stratification revealed a profound disparity: the 2-year RFS was significantly lower in the VEGF-high group (77.4 %) compared to the VEGF-low group (94.9 %, P < 0.001). While extended resection provided a higher 2-year RFS than curettage (96.0 % vs. 79.5 %, P < 0.001), it incurred greater operative burden and complication risks. Crucially, multivariate analysis established high VEGF expression as the most powerful independent predictor of recurrence (HR = 45.15, P < 0.001), with a risk magnitude exceeding that of curettage (HR = 37.22, P < 0.001).
CONCLUSION: High VEGF mRNA expression is a powerful, independent biomarker for AM recurrence, with a prognostic impact surpassing surgical choice. Preoperative VEGF assessment holds significant potential for guiding individualized surgical planning and optimizing follow-up strategies.
METHODS: A retrospective cohort study was conducted involving 200 patients with primary AM undergoing initial surgery during January 2021-December 2023. Patients were categorized into curettage (n = 77) and extended resection (n = 123) groups. Relative VEGF mRNA expression in the tumor cyst wall was quantified using RT-qPCR. Kaplan-Meier analysis and Cox regression were used to analyze recurrence-free survival (RFS) and risk factors. Perioperative outcomes and complications were compared between groups. Univariate and multivariate analyses were performed using Cox proportional hazards regression models.
RESULTS: VEGF mRNA expression was significantly elevated in the recurrence group (4.66 ± 1.42) versus the non-recurrence group (3.24 ± 2.02, P < 0.001). ROC curve analysis identified an optimal VEGF cutoff value of 4.88 for predicting recurrence (AUC = 0.694). This molecular stratification revealed a profound disparity: the 2-year RFS was significantly lower in the VEGF-high group (77.4 %) compared to the VEGF-low group (94.9 %, P < 0.001). While extended resection provided a higher 2-year RFS than curettage (96.0 % vs. 79.5 %, P < 0.001), it incurred greater operative burden and complication risks. Crucially, multivariate analysis established high VEGF expression as the most powerful independent predictor of recurrence (HR = 45.15, P < 0.001), with a risk magnitude exceeding that of curettage (HR = 37.22, P < 0.001).
CONCLUSION: High VEGF mRNA expression is a powerful, independent biomarker for AM recurrence, with a prognostic impact surpassing surgical choice. Preoperative VEGF assessment holds significant potential for guiding individualized surgical planning and optimizing follow-up strategies.